Dubuque Bank & Trust Co. Purchases 799 Shares of Bristol-Myers Squibb Co (NYSE:BMY)
Dubuque Bank & Trust Co. grew its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 8.7% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 10,010 shares of the biopharmaceutical company’s stock after acquiring an additional 799 shares during the period. Dubuque Bank & Trust Co.’s holdings in Bristol-Myers Squibb were worth $642,000 at the end of the most recent quarter.
Several other large investors have also recently made changes to their positions in the company. Schroder Investment Management Group increased its holdings in shares of Bristol-Myers Squibb by 6.1% during the second quarter. Schroder Investment Management Group now owns 4,690,132 shares of the biopharmaceutical company’s stock worth $212,698,000 after buying an additional 270,185 shares in the last quarter. Lido Advisors LLC boosted its holdings in shares of Bristol-Myers Squibb by 25.1% during the 2nd quarter. Lido Advisors LLC now owns 17,893 shares of the biopharmaceutical company’s stock valued at $811,000 after acquiring an additional 3,594 shares in the last quarter. National Pension Service boosted its holdings in shares of Bristol-Myers Squibb by 6.0% during the 2nd quarter. National Pension Service now owns 1,693,877 shares of the biopharmaceutical company’s stock valued at $76,817,000 after acquiring an additional 96,363 shares in the last quarter. Holocene Advisors LP bought a new stake in Bristol-Myers Squibb during the 2nd quarter worth $9,860,000. Finally, Rock Springs Capital Management LP bought a new stake in Bristol-Myers Squibb during the 2nd quarter worth $47,618,000. 83.02% of the stock is owned by hedge funds and other institutional investors.
In related news, insider Louis S. Schmukler sold 25,000 shares of Bristol-Myers Squibb stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $56.56, for a total transaction of $1,414,000.00. Following the completion of the transaction, the insider now owns 31,963 shares of the company’s stock, valued at $1,807,827.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP John E. Elicker sold 15,000 shares of the business’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $56.66, for a total transaction of $849,900.00. Following the completion of the transaction, the senior vice president now owns 74,471 shares in the company, valued at approximately $4,219,526.86. The disclosure for this sale can be found here. Corporate insiders own 0.13% of the company’s stock.
Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.17 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.06 by $0.11. Bristol-Myers Squibb had a return on equity of 45.49% and a net margin of 23.53%. The business had revenue of $6.01 billion for the quarter, compared to analysts’ expectations of $5.89 billion. During the same period in the prior year, the business posted $1.09 earnings per share. The firm’s revenue was up 5.6% on a year-over-year basis. On average, analysts predict that Bristol-Myers Squibb Co will post 4.47 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Monday, February 3rd. Stockholders of record on Friday, January 3rd will be paid a $0.45 dividend. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.41. This represents a $1.80 dividend on an annualized basis and a dividend yield of 2.71%. The ex-dividend date is Thursday, January 2nd. Bristol-Myers Squibb’s dividend payout ratio is currently 45.23%.
BMY has been the subject of several research reports. UBS Group increased their target price on Bristol-Myers Squibb from $51.00 to $53.00 and gave the company a “neutral” rating in a research report on Wednesday, October 23rd. ValuEngine upgraded Bristol-Myers Squibb from a “strong sell” rating to a “sell” rating in a report on Tuesday, November 19th. Citigroup raised Bristol-Myers Squibb from a “neutral” rating to a “buy” rating and set a $73.00 price objective for the company in a research note on Monday, January 6th. William Blair reiterated a “buy” rating on shares of Bristol-Myers Squibb in a report on Friday, December 13th. Finally, Argus upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $80.00 target price on the stock in a research report on Friday, December 13th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and fourteen have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $61.69.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Featured Story: Price-Sales Ratio
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.